Modulation of Drug Resistance in Ovarian Cancer Cells by Inhibition of Protein Kinase C-alpha (Pkc-Α) with Small Interference RNA (sirna) Agents.

Lijun Zhao,Heng Xu,Jiantao Qu,Wanzhou Zhao,Yibing Zhao,Jinhua Wang

DOI: https://doi.org/10.7314/apjcp.2012.13.8.3631

2012-01-01

Asian Pacific Journal of Cancer Prevention

Abstract:To determine whether silence of PKC-α expression by small interference RNA (siRNA) might regulate MDR1 expression and reverse chemoresistance of ovarian cancer.We measured gene and protein expression of MDR1 and PKC-α in ovarian cancer cells and assessed their correlation with cell drug resistance. We also examined whether blocking PKC-α by RNA interference (RNAi) affected MDR1 expression and reversed drug resistance in drug sensitivity tests.The drug resistance cell lines, OV1228/DDP and OV1228/Taxol, had higher gene and protein expression of MDR1 and PKC-α than their counterpart sensitive cell line, OV1228. SiRNA depressed PKC-α gene protein expression, as well as MDR1 and protein expression and improved the drug sensitivity in OV1228/DDP and OV1228/Taxol cells.These results indicated that decreasing PKC-α expression with siRNA might be an effective method to improve drug sensitivity in drug resistant cells with elevated levels of PKC-α and MDR1. A new siRNA-based therapeutic strategy targeting PKC-α gene could be designed to overcome the chemoresistance of ovarian cancer.